Kandy Therapeutics

Breakthrough treatment for chronic debilitating Women’s Health conditions

KaNDy Therapeutics is a UK based clinical-stage company focused on optimizing the potential of NT-814 as a breakthrough medicine for the treatment of chronic debilitating Women’s Health conditions.

NT-814 is a first-in-class, once daily, dual mechanism neurokinin-1,3 receptor antagonist. The medicine is being developed as a non-hormonal alternative to hormone replacement therapy for the treatment of postmenopausal symptoms (PMS).

NT-814 has been spun out of NeRRe Therapeutics Holdings Ltd into KaNDy Therapeutics Ltd, a separate legal entity. The new company will advance the development of NT-814 into Phase 2b in the lead indication PMS while also exploring its potential in other Women’s Health indications. All formulation, pre-clinical and clinical safety and efficacy data, and intellectual property associated with NT-814 have been transferred to the new company.

CEO  Mary Kerr

Advent Contact  Kaasim Mahmood

Exited Insvestment
26 May 2022 in Advent Life Sciences, Press Release

Advent Life Sciences Announces Growth of Investment Team with Three Senior Appointments

Press Release.   26 May 2022, London, UK: Advent Life Sciences, a leading transatlantic venture and growth investor focused on building innovative life science companies in the UK, Europe, and…
Read More
17 March 2021 in Advent Life Sciences, Press Release

Advent Life Sciences’ founded Amphista Therapeutics raises $53M in oversubscribed Series B round to advance next generation targeted protein degradation assets

Press Release.   This investment will fund Amphista Therapeutics’  growing pipeline of potent and selective bifunctional molecules, known as ‘Amphistas’ to the clinic and extend its proprietary platform. London, UK,…
Read More
12 March 2021 in Advent Life Sciences, Press Release

Advent Life Sciences Becomes Latest Partner of One Nucleus

Press Release.   Cambridge and London UK: 12th March 2021 Advent Life Sciences, one of the sector’s leading Trans-Atlantic venture investors has become the latest Partner to join One Nucleus.…
Read More
18 February 2021 in Advent Life Sciences, Press Release

Advent Life Sciences Announces Close of Two New Funds Totalling $215 million

Press Release.   18 February 2021, London, UK: Advent Life Sciences, a leading transatlantic venture investor focused on building innovative life science companies in the UK, Europe and the US,…
Read More